Related Experiment Video
Updated: Jun 18, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
Rhabdomyosarcoma fusion oncoprotein initially pioneers a neural signature in vivo
Abstract:
Fusion-positive rhabdomyosarcoma is an aggressive pediatric cancer molecularly characterized by arrested myogenesis. The defining genetic driver, PAX3::FOXO1, functions as a chimeric gain-of-function transcription factor. An incomplete understanding of PAX3::FOXO1's in vivo epigenetic mechanisms has hindered therapeutic development. Here, we establish a PAX3::FOXO1 zebrafish injection model and semi-automated ChIP-seq normalization strategy to evaluate how PAX3::FOXO1 initially interfaces with chromatin in a developmental context. We investigated PAX3::FOXO1's recognition of chromatin and subsequent transcriptional consequences. We find that PAX3::FOXO1 interacts with inaccessible chromatin through partial/homeobox motif recognition consistent with pioneering activity. However, PAX3::FOXO1-genome binding through a composite paired-box/homeobox motif alters chromatin accessibility and redistributes H3K27ac to activate neural transcriptional programs. We uncover neural signatures that are highly representative of clinical rhabdomyosarcoma gene expression programs that are enriched following chemotherapy. Overall, we identify partial/homeobox motif recognition as a new mode for PAX3::FOXO1 pioneer function and identify neural signatures as a potentially critical PAX3::FOXO1 tumor initiation event.
Insights
Pediatric rhabdomyosarcoma is driven by PAX3::FOXO1, which pioneers inaccessible chromatin. This interaction activates neural gene programs, revealing a critical event in tumor initiation.
Area of Science:
- Oncology
- Molecular Biology
- Developmental Biology
Background:
- Fusion-positive rhabdomyosarcoma is an aggressive pediatric cancer.
- The PAX3::FOXO1 fusion protein is the primary genetic driver.
- Current understanding of its in vivo epigenetic mechanisms is limited, hindering therapeutic development.
Purpose of the Study:
- To investigate how PAX3::FOXO1 interacts with chromatin in vivo.
- To understand the epigenetic mechanisms and transcriptional consequences of PAX3::FOXO1 binding.
- To identify potential therapeutic targets for rhabdomyosarcoma.
Main Methods:
- Established a PAX3::FOXO1 zebrafish injection model.
- Developed a semi-automated ChIP-seq normalization strategy.
- Analyzed PAX3::FOXO1 genome binding, chromatin accessibility, and H3K27ac redistribution.
Main Results:
- PAX3::FOXO1 pioneers inaccessible chromatin via partial/homeobox motif recognition.
- PAX3::FOXO1 binding alters chromatin accessibility and redistributes H3K27ac.
- Activated neural transcriptional programs and signatures were identified, mirroring clinical rhabdomyosarcoma profiles.
Conclusions:
- Partial/homeobox motif recognition is a novel mode of PAX3::FOXO1 pioneer function.
- Neural signatures represent a critical PAX3::FOXO1-driven tumor initiation event.
- Findings offer new insights into rhabdomyosarcoma pathogenesis and potential therapeutic strategies.
Related Concept Videos
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MAPK Signaling Cascades

